

BIOSPECIFICS TECHNOLOGIES CORP

Form 8-K

April 18, 2017

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, DC 20549

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **April 18, 2017**

**BIOSPECIFICS TECHNOLOGIES CORP.**

(Exact name of registrant as specified in its charter)

**Delaware**

(State or other jurisdiction  
of incorporation)

**001-34236**

(Commission  
File Number)

**11-3054851**

(IRS Employer  
Identification No.)

**35 Wilbur Street**

**Lynbrook, NY**

(Address of principal executive offices)

**11563**

(Zip Code)

Registrant's telephone number, including area code: **516.593.7000**

**N/A**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

---

**Introductory Comment**

Throughout this Current Report on Form 8-K, the terms we, us, our and Company refer to BioSpecifics Technologies Corp.

**Item 8.01. Other Events**

On April 18, 2017, BioSpecifics announced the initiation of its Phase 1 clinical trial of XIAFLEX® for the treatment of uterine fibroids.

A press release regarding the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K.

**Item 9.01. Financial Statements and Exhibits**

(d) Exhibits.

**Exhibit Description**

<u>99.1</u>	<u>Press Release dated April 18, 2017</u>
-------------	---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: April 18, 2017

**BioSpecifics Technologies Corp.**

By: /s/ Thomas L. Wegman  
Name: Thomas L. Wegman  
Title: President

3

---

**EXHIBIT INDEX**

**Exhibit** **Description**  
**No.**

99.1 Press Release dated April 18, 2017

4